A case of primary malignant melanoma of the lung responded to anti-PD-1 antibody therapy

Ikuko Hirai, Keiji Tanese, Shoko Obata, Takeru Funakoshi

Research output: Contribution to journalArticle

Abstract

Primary malignant melanoma of the lung (PMML) is an exceedingly rare type of melanoma. Here, we report a case of an 86-year-old Japanese woman who was diagnosed as PMML with subcarinal lymph node metastasis. She was treated with intravenous administration of programmed cell death-1 (PD-1) inhibitor, nivolumab. After the treatment, lymph node lesion regressed. The size of primary lesion was also controlled in combination with radiotherapy. In this case, two histological features were noted in the biopsy specimen that supported a response to nivolumab: membranous expression of programmed death ligand-1 (PD-L1) in tumor cells and dense scattered infiltration of CD8+ TILs. The clinical course of this case suggests that certain PMML cases may also respond to anti-PD-1 therapy.

Original languageEnglish
Pages (from-to)173-175
Number of pages3
JournalIndian Journal of Thoracic and Cardiovascular Surgery
Volume33
Issue number2
DOIs
Publication statusPublished - 2017 Jun 1

Fingerprint

Melanoma
Cell Death
Lung
Antibodies
Lymph Nodes
Therapeutics
Intravenous Administration
Radiotherapy
Neoplasm Metastasis
Ligands
Biopsy
Neoplasms
nivolumab

Keywords

  • Primary malignant melanoma of the lung
  • Programmed cell death 1(PD-1)
  • Tumor infiltrating lymphocytes (TIL)

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

A case of primary malignant melanoma of the lung responded to anti-PD-1 antibody therapy. / Hirai, Ikuko; Tanese, Keiji; Obata, Shoko; Funakoshi, Takeru.

In: Indian Journal of Thoracic and Cardiovascular Surgery, Vol. 33, No. 2, 01.06.2017, p. 173-175.

Research output: Contribution to journalArticle

@article{f550374bcc454765ae901f19d1db001e,
title = "A case of primary malignant melanoma of the lung responded to anti-PD-1 antibody therapy",
abstract = "Primary malignant melanoma of the lung (PMML) is an exceedingly rare type of melanoma. Here, we report a case of an 86-year-old Japanese woman who was diagnosed as PMML with subcarinal lymph node metastasis. She was treated with intravenous administration of programmed cell death-1 (PD-1) inhibitor, nivolumab. After the treatment, lymph node lesion regressed. The size of primary lesion was also controlled in combination with radiotherapy. In this case, two histological features were noted in the biopsy specimen that supported a response to nivolumab: membranous expression of programmed death ligand-1 (PD-L1) in tumor cells and dense scattered infiltration of CD8+ TILs. The clinical course of this case suggests that certain PMML cases may also respond to anti-PD-1 therapy.",
keywords = "Primary malignant melanoma of the lung, Programmed cell death 1(PD-1), Tumor infiltrating lymphocytes (TIL)",
author = "Ikuko Hirai and Keiji Tanese and Shoko Obata and Takeru Funakoshi",
year = "2017",
month = "6",
day = "1",
doi = "10.1007/s12055-017-0488-z",
language = "English",
volume = "33",
pages = "173--175",
journal = "Indian Journal of Thoracic and Cardiovascular Surgery",
issn = "0970-9134",
publisher = "Association of Thoracic and Cardiovascular Surgeons of India",
number = "2",

}

TY - JOUR

T1 - A case of primary malignant melanoma of the lung responded to anti-PD-1 antibody therapy

AU - Hirai, Ikuko

AU - Tanese, Keiji

AU - Obata, Shoko

AU - Funakoshi, Takeru

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Primary malignant melanoma of the lung (PMML) is an exceedingly rare type of melanoma. Here, we report a case of an 86-year-old Japanese woman who was diagnosed as PMML with subcarinal lymph node metastasis. She was treated with intravenous administration of programmed cell death-1 (PD-1) inhibitor, nivolumab. After the treatment, lymph node lesion regressed. The size of primary lesion was also controlled in combination with radiotherapy. In this case, two histological features were noted in the biopsy specimen that supported a response to nivolumab: membranous expression of programmed death ligand-1 (PD-L1) in tumor cells and dense scattered infiltration of CD8+ TILs. The clinical course of this case suggests that certain PMML cases may also respond to anti-PD-1 therapy.

AB - Primary malignant melanoma of the lung (PMML) is an exceedingly rare type of melanoma. Here, we report a case of an 86-year-old Japanese woman who was diagnosed as PMML with subcarinal lymph node metastasis. She was treated with intravenous administration of programmed cell death-1 (PD-1) inhibitor, nivolumab. After the treatment, lymph node lesion regressed. The size of primary lesion was also controlled in combination with radiotherapy. In this case, two histological features were noted in the biopsy specimen that supported a response to nivolumab: membranous expression of programmed death ligand-1 (PD-L1) in tumor cells and dense scattered infiltration of CD8+ TILs. The clinical course of this case suggests that certain PMML cases may also respond to anti-PD-1 therapy.

KW - Primary malignant melanoma of the lung

KW - Programmed cell death 1(PD-1)

KW - Tumor infiltrating lymphocytes (TIL)

UR - http://www.scopus.com/inward/record.url?scp=85021702058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021702058&partnerID=8YFLogxK

U2 - 10.1007/s12055-017-0488-z

DO - 10.1007/s12055-017-0488-z

M3 - Article

VL - 33

SP - 173

EP - 175

JO - Indian Journal of Thoracic and Cardiovascular Surgery

JF - Indian Journal of Thoracic and Cardiovascular Surgery

SN - 0970-9134

IS - 2

ER -